EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types

Elodie Verdier, Nathalie Gaspar, Maria Eugenia Marques Da Costa, Antonin Marchais

Oncotarget · 2025

DOI: 10.18632/oncotarget.28688 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncotarget, 2025. Verfasst von Elodie Verdier und 3 weiteren Autor:innen. Beteiligte Einrichtung: UMR 1015 Tumour Immunology and anti-cancer immunotherapy Unit, Gustave Roussy Cancer Campus, Villejuif 94800, France. Hauptthemen laut MEDLINE: Osteosarcoma, Histone-Lysine N-Methyltransferase, Gene Amplification, Bone Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic modifications, which reversibly regulate gene expression without altering the DNA sequence, are increasingly described in the literature as essential elements in the processes leading to cancer development. SETDB1 regulates histone 3 (H3) K9 di- and trimethylation, promoting heterochromatin formation, and plays a key role in gene silencing. Epigenetic deregulation of SETDB1 expression appears to be involved in different cancers types, particularly in aggressive, relapsing or treatment-resistant subtypes. Despite advances in research, the full range of mechanisms through which this protein acts remains unclear; however, it is evident that SETDB1 has a pivotal role, particularly in the mesenchymal stem cells differentiation, tumor evasion and treatment resistance. Its role in genetically complex sarcomas, such as osteosarcoma, has not been fully explored, although recent Omics analyses suggest its presence and amplification in osteosarcoma. Given its involvement in osteoblastogenesis and adipogenesis, we discuss the potential of SETDB1 as a key target for new therapeutic strategies in osteosarcoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaHistone-Lysine N-MethyltransferaseGene AmplificationBone NeoplasmsHumansEpigenesis, GeneticAnimalsGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

SETDB1cancer epigeneticsmesenchymal differentiation in osteosarcomatumor immunogenicity

Substanzen

Histone-Lysine N-MethyltransferaseSETDB1 protein, human

Autor:innen und Institutionen

  • UMR 1015 Tumour Immunology and anti-cancer immunotherapy Unit, Gustave Roussy Cancer Campus, Villejuif 94800, France.
  • Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif 94805, France.

Zitieren

APA

Verdier, E., Gaspar, N., Marques Da Costa, M. E., & Marchais, A. (2025). SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types. Oncotarget. https://doi.org/10.18632/oncotarget.28688

Vancouver

Verdier E, Gaspar N, Marques Da Costa ME, Marchais A. SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types. Oncotarget. 2025. doi:10.18632/oncotarget.28688

BibTeX
@article{Verdier2025,
  author = {Verdier, Elodie and Gaspar, Nathalie and Marques Da Costa, Maria Eugenia and Marchais, Antonin},
  title = {SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types},
  journal = {Oncotarget},
  year = {2025},
  doi = {10.18632/oncotarget.28688}
}
Kostenlos starten →